Costs Are “Valid” Selection Factor In Medicare “Coverage With Evidence Development” Option – NIH Bioethicists
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare CED policy does not compromise ethical standards for medical research, they conclude in JAMA commentary.
You may also be interested in...
CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance
The agency aims to clarify its rationale and solidify the legal basis for requiring data collection as a condition of national Medicare coverage in guidelines issued July 12.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.